Other languages FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Market Closed - Canadian Securities Exchange Other stock markets 01:29:02 04/05/2024 am IST			5-day change	1st Jan Change
0.52 ^CAD	+1.96%		-21.21%	-56.67%

30/04	FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	CI
25/04	FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

FSD Pharma Inc. Signs Agreement with Applied Science and Performance Institute to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of Unbuzzd? in an Induced State of Alcohol Intoxication	30/04
FSD Pharma Says Celly Nutrition Partners with Six+One for US Launch of Dietary Supplement	25/04
FSD Pharma Receives Nasdaq Non-Compliance Notice	08/04
FSD Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd	11/03
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum	05/03
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma	20/02
FSD Pharma Inc. Announces Board Changes	30/01
FSD Pharma Inc. completed the Spin-Off of Celly Nutrition Corp.	29/11
FSD Pharma Inc. Announces Change of CEO	16/11
FSD Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11
FSD Pharma Enters Agreement on Distribution of Portion of Celly Nutrition Shareholdings	05/23/05
FSD Pharma Inc. agreed to Spin-Off 34.66% stake of Celly Nutrition Corp.	04/23/04
FSD Pharma Shares Rise After Saying Interim Report Shows Multiple Sclerosis Treatment Candidate Safe, Well-Tolerated	18/23/18
FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis	18/23/18
FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023	15/23/15
FSD Pharma Inc. Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink	02/23/02
FSD Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/23/21
FSD Pharma Inc. Announces CEO Changes	04/23/04
FSD Pharma Inc. Approves Election of Michael Zapolin as Director	30/23/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages FSD Pharma Inc.

Equities

HUGE

CA35954B4047

Other languages

Filters